复发难治性急性髓系白血病临床治疗的疗效观察  

Clinical Observation on the Clinical Treatment of Recurrent Refractory acute Myeloid Leukemia

作　　者：张梅儒 段宝英[1] 王志霞 刘婷婷 高溧鲜 ZHANG Meiru;DUAN Baoying;WANG Zhixia;LIU Tingting;GAO Lixian(the First People's Hospital of Baiyin City,Baiyin 730900,China)

机构地区：[1]甘肃白银市第一人民医院,甘肃白银730900

出　　处：《中国医药指南》2021年第21期48-49,共2页Guide of China Medicine

摘　　要：目的探讨复发难治性急性髓系白血病临床治疗的疗效。方法将我院2017年1月至2018年1月的160例复发难治性急性髓系白血病患者,随机分组,CAG方案治疗组(n=80)对复发难治性急性髓系白血病患者给予CAG方案治疗,CAG方案联合地西他滨治疗组(n=80)对复发难治性急性髓系白血病患者开展CAG方案联合地西他滨治疗。比较两组临床治疗效果。结果CAG方案联合地西他滨治疗组的治疗效果等指标优于CAG方案治疗组,P<0.05;CAG方案联合地西他滨治疗组不良反应发生率和CAG方案治疗组的不良反应发生率比较无差异,P>0.05。结论复发难治性急性髓系白血病患者实施CAG方案联合地西他滨治疗效果确切,可有效改善复发难治性急性髓系白血病患者的生活质量,加速患者病情的改善,且无严重不良反应。Objective To explore the efficacy of clinical treatment of relapsed and refractory acute myeloid leukemia.Methods A total of 160 patients with relapsed and refractory acute myeloid leukemia in our hospital from January 2017 to January 2018 were randomly divided into groups,and the CAG regimen treatment group(n=80)was given the CAG regimen and the CAG regimen combined with the CAG regimen treatment group.In the decitabine treatment group(n=80),the CAG regimen combined with decitabine was used to treat patients with relapsed and refractory acute myeloid leukemia.Compare the clinical treatment effects of the two groups.Results The treatment effect and other indicators of the CAG regimen combined with decitabine treatment group were better than those of the CAG regimen treatment group,P<0.05;there was no difference in the incidence of adverse reactions between the CAG regimen combined with decitabine treatment group and the CAG regimen treatment group,P>0.05.Conclusion For patients with relapsed and refractory acute myeloid leukemia,the CAG regimen combined with decitabine has a definite effect,which can effectively improve the quality of life of patients with relapsed and refractory acute myeloid leukemia,accelerate the improvement of the patient's condition,and have no serious adverse reactions.

关 键 词：复发难治性急性髓系白血病 临床治疗 疗效 

分 类 号：R737.71[医药卫生—肿瘤]